GSK Signs Deal With Epix For GPCR Candidates
Epix will be eligible to earn milestones of $1.2 billion based on development and commercialization of four programs, including a Phase II Alzheimer’s molecule.
Epix will be eligible to earn milestones of $1.2 billion based on development and commercialization of four programs, including a Phase II Alzheimer’s molecule.